TW201642847A - 用於靜脈內投與反丁烯二酸酯以治療神經疾病之方法及組合物 - Google Patents

Info

Publication number

TW201642847A

TW201642847A TW105108578A TW105108578A TW201642847A TW 201642847 A TW201642847 A TW 201642847A TW 105108578 A TW105108578 A TW 105108578A TW 105108578 A TW105108578 A TW 105108578A TW 201642847 A TW201642847 A TW 201642847A

Authority

TW

Taiwan

Prior art keywords

fumarate

pharmaceutical composition

patient

dimethyl

intravenous administration

Prior art date

2015-03-20

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 455
• 238000001990 intravenous administration Methods 0.000 title claims abstract description 145
• 238000011282 treatment Methods 0.000 title claims abstract description 80
• 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 41
• 239000000203 mixture Substances 0.000 title claims abstract description 29
• 208000025966 Neurological disease Diseases 0.000 title claims abstract description 16
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 title abstract description 9
• 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 96
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 60
• 208000023105 Huntington disease Diseases 0.000 claims abstract description 57
• 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 37
• 208000018737 Parkinson disease Diseases 0.000 claims abstract description 28
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 564
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 542
• 150000001875 compounds Chemical class 0.000 claims description 386
• LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical group COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 264
• 229960004419 dimethyl fumarate Drugs 0.000 claims description 258
• 230000006378 damage Effects 0.000 claims description 235
• 239000008194 pharmaceutical composition Substances 0.000 claims description 197
• 239000013543 active substance Substances 0.000 claims description 92
• 150000003839 salts Chemical class 0.000 claims description 90
• -1 dimethyl fumarate ester Chemical class 0.000 claims description 85
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 67
• 201000010099 disease Diseases 0.000 claims description 62
• NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 57
• NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 56
• 229940005650 monomethyl fumarate Drugs 0.000 claims description 56
• 229940002612 prodrug Drugs 0.000 claims description 56
• 239000000651 prodrug Substances 0.000 claims description 56
• 229920000858 Cyclodextrin Polymers 0.000 claims description 44
• 239000003814 drug Substances 0.000 claims description 36
• 229940079593 drug Drugs 0.000 claims description 35
• 239000001530 fumaric acid Substances 0.000 claims description 32
• 150000002148 esters Chemical class 0.000 claims description 30
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 28
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 27
• 229960004853 betadex Drugs 0.000 claims description 27
• 239000007864 aqueous solution Substances 0.000 claims description 22
• 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 22
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 22
• 239000001116 FEMA 4028 Substances 0.000 claims description 20
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
• 230000009885 systemic effect Effects 0.000 claims description 17
• 229960005027 natalizumab Drugs 0.000 claims description 15
• 238000011269 treatment regimen Methods 0.000 claims description 15
• 206010020751 Hypersensitivity Diseases 0.000 claims description 14
• 210000000987 immune system Anatomy 0.000 claims description 14
• 229940124622 immune-modulator drug Drugs 0.000 claims description 14
• 230000001506 immunosuppresive effect Effects 0.000 claims description 14
• 229940124589 immunosuppressive drug Drugs 0.000 claims description 14
• 239000000644 isotonic solution Substances 0.000 claims description 14
• 230000000750 progressive effect Effects 0.000 claims description 14
• 230000001771 impaired effect Effects 0.000 claims description 13
• 239000006070 nanosuspension Substances 0.000 claims description 12
• 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 10
• HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 10
• 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 10
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 10
• 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 9
• 239000003381 stabilizer Substances 0.000 claims description 8
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 6
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 6
• 239000000872 buffer Substances 0.000 claims description 4
• 239000008363 phosphate buffer Substances 0.000 claims description 4
• 150000003384 small molecules Chemical class 0.000 claims description 4
• 239000011734 sodium Substances 0.000 claims description 4
• 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 4
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
• 239000002245 particle Substances 0.000 claims description 3
• 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 2
• VHDIUHAEPNGGSD-TYYBGVCCSA-N O1CCOCC1.C(\C=C\C(=O)O)(=O)O Chemical compound O1CCOCC1.C(\C=C\C(=O)O)(=O)O VHDIUHAEPNGGSD-TYYBGVCCSA-N 0.000 claims 5
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
• IUMSESXEXDXETG-UHFFFAOYSA-N [Na].CCCCCCCCCCCC[S] Chemical group [Na].CCCCCCCCCCCC[S] IUMSESXEXDXETG-UHFFFAOYSA-N 0.000 claims 1
• 208000006011 Stroke Diseases 0.000 abstract description 106
• 125000000217 alkyl group Chemical group 0.000 description 214
• 229910052739 hydrogen Inorganic materials 0.000 description 125
• 239000001257 hydrogen Substances 0.000 description 125
• 208000027418 Wounds and injury Diseases 0.000 description 104
• 208000014674 injury Diseases 0.000 description 104
• 238000012360 testing method Methods 0.000 description 101
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 94
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 93
• 230000006735 deficit Effects 0.000 description 57
• 239000003981 vehicle Substances 0.000 description 56
• 125000003118 aryl group Chemical group 0.000 description 52
• 230000006870 function Effects 0.000 description 48
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 40
• 125000005842 heteroatom Chemical group 0.000 description 40
• 229910052757 nitrogen Inorganic materials 0.000 description 40
• 206010012289 Dementia Diseases 0.000 description 38
• 229910052760 oxygen Inorganic materials 0.000 description 38
• 230000008859 change Effects 0.000 description 37
• 210000004556 brain Anatomy 0.000 description 36
• 229910052717 sulfur Inorganic materials 0.000 description 36
• 230000006872 improvement Effects 0.000 description 35
• 230000003902 lesion Effects 0.000 description 32
• 125000001072 heteroaryl group Chemical group 0.000 description 30
• 208000010877 cognitive disease Diseases 0.000 description 29
• 208000028698 Cognitive impairment Diseases 0.000 description 28
• 125000004432 carbon atom Chemical group C* 0.000 description 27
• 150000002431 hydrogen Chemical group 0.000 description 27
• 230000033001 locomotion Effects 0.000 description 26
• 230000000694 effects Effects 0.000 description 25
• 108090000623 proteins and genes Proteins 0.000 description 25
• 125000001424 substituent group Chemical group 0.000 description 25
• 208000024891 symptom Diseases 0.000 description 25
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 23
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 23
• 125000004433 nitrogen atom Chemical group N* 0.000 description 22
• 210000001364 upper extremity Anatomy 0.000 description 22
• 238000011156 evaluation Methods 0.000 description 21
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 20
• 230000009747 swallowing Effects 0.000 description 20
• 230000002354 daily effect Effects 0.000 description 19
• 230000005021 gait Effects 0.000 description 18
• 125000000623 heterocyclic group Chemical group 0.000 description 18
• 241000699670 Mus sp. Species 0.000 description 17
• 125000005647 linker group Chemical group 0.000 description 17
• 125000003710 aryl alkyl group Chemical group 0.000 description 16
• 229910052799 carbon Inorganic materials 0.000 description 16
• 150000004702 methyl esters Chemical class 0.000 description 16
• 230000008569 process Effects 0.000 description 16
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
• 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 15
• 101710109147 Glutamate-cysteine ligase catalytic subunit Proteins 0.000 description 15
• 210000003205 muscle Anatomy 0.000 description 15
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 15
• 210000001519 tissue Anatomy 0.000 description 15
• 210000003414 extremity Anatomy 0.000 description 14
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 14
• 210000003141 lower extremity Anatomy 0.000 description 14
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
• 101150075804 nqo1 gene Proteins 0.000 description 14
• 238000012552 review Methods 0.000 description 14
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 13
• 229910052805 deuterium Inorganic materials 0.000 description 13
• 101710088194 Dehydrogenase Proteins 0.000 description 12
• 108010018924 Heme Oxygenase-1 Proteins 0.000 description 12
• 102000002737 Heme Oxygenase-1 Human genes 0.000 description 12
• 102000016173 Oxidative stress-induced growth inhibitor 1 Human genes 0.000 description 12
• 108050004650 Oxidative stress-induced growth inhibitor 1 Proteins 0.000 description 12
• 238000012879 PET imaging Methods 0.000 description 12
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 12
• 238000000540 analysis of variance Methods 0.000 description 12
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 12
• 230000015556 catabolic process Effects 0.000 description 12
• 238000006731 degradation reaction Methods 0.000 description 12
• 229910052736 halogen Inorganic materials 0.000 description 12
• 150000002367 halogens Chemical class 0.000 description 12
• 230000015654 memory Effects 0.000 description 12
• 230000007659 motor function Effects 0.000 description 12
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 12
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 11
• 101150044653 HMOX1 gene Proteins 0.000 description 11
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 11
• 230000006399 behavior Effects 0.000 description 11
• 230000003542 behavioural effect Effects 0.000 description 11
• 125000002837 carbocyclic group Chemical group 0.000 description 11
• 230000001055 chewing effect Effects 0.000 description 11
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 10
• 239000002253 acid Substances 0.000 description 10
• 238000004458 analytical method Methods 0.000 description 10
• 150000001721 carbon Chemical group 0.000 description 10
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 10
• 210000001630 jejunum Anatomy 0.000 description 10
• 210000003734 kidney Anatomy 0.000 description 10
• 238000007726 management method Methods 0.000 description 10
• 125000003386 piperidinyl group Chemical group 0.000 description 10
• 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 9
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 9
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 9
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 9
• 101150005894 GCLC gene Proteins 0.000 description 9
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 9
• 102000004316 Oxidoreductases Human genes 0.000 description 9
• 108090000854 Oxidoreductases Proteins 0.000 description 9
• 206010033799 Paralysis Diseases 0.000 description 9
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
• 229960002478 aldosterone Drugs 0.000 description 9
• 210000003811 finger Anatomy 0.000 description 9
• 230000009760 functional impairment Effects 0.000 description 9
• 238000010348 incorporation Methods 0.000 description 9
• 238000005259 measurement Methods 0.000 description 9
• 230000003340 mental effect Effects 0.000 description 9
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 9
• 230000000926 neurological effect Effects 0.000 description 9
• 238000012216 screening Methods 0.000 description 9
• 206010003591 Ataxia Diseases 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
• 230000001149 cognitive effect Effects 0.000 description 8
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 8
• 230000008449 language Effects 0.000 description 8
• 230000006996 mental state Effects 0.000 description 8
• 210000002161 motor neuron Anatomy 0.000 description 8
• 210000002381 plasma Anatomy 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 7
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 7
• 208000010428 Muscle Weakness Diseases 0.000 description 7
• 206010028372 Muscular weakness Diseases 0.000 description 7
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 7
• 125000002619 bicyclic group Chemical group 0.000 description 7
• 206010016256 fatigue Diseases 0.000 description 7
• 125000002950 monocyclic group Chemical group 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 229920006395 saturated elastomer Polymers 0.000 description 7
• 230000002103 transcriptional effect Effects 0.000 description 7
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• 206010022998 Irritability Diseases 0.000 description 6
• KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 6
• 230000001154 acute effect Effects 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 239000012084 conversion product Substances 0.000 description 6
• 125000006165 cyclic alkyl group Chemical group 0.000 description 6
• 125000000753 cycloalkyl group Chemical group 0.000 description 6
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
• 230000006866 deterioration Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 6
• 238000003384 imaging method Methods 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 230000001976 improved effect Effects 0.000 description 6
• 238000001727 in vivo Methods 0.000 description 6
• 238000012423 maintenance Methods 0.000 description 6
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
• 210000002569 neuron Anatomy 0.000 description 6
• 238000012353 t test Methods 0.000 description 6
• 206010008748 Chorea Diseases 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 206010027374 Mental impairment Diseases 0.000 description 5
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
• 206010049816 Muscle tightness Diseases 0.000 description 5
• 208000028017 Psychotic disease Diseases 0.000 description 5
• 229910005965 SO 2 Inorganic materials 0.000 description 5
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
• 101150074234 TXNRD1 gene Proteins 0.000 description 5
• 108010093836 Thioredoxin Reductase 1 Proteins 0.000 description 5
• 102000001639 Thioredoxin Reductase 1 Human genes 0.000 description 5
• 125000003342 alkenyl group Chemical group 0.000 description 5
• 230000002238 attenuated effect Effects 0.000 description 5
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 208000012601 choreatic disease Diseases 0.000 description 5
• 230000003920 cognitive function Effects 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 230000005714 functional activity Effects 0.000 description 5
• 230000000155 isotopic effect Effects 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 229940068196 placebo Drugs 0.000 description 5
• 239000000902 placebo Substances 0.000 description 5
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
• 229910052707 ruthenium Inorganic materials 0.000 description 5
• 208000011580 syndromic disease Diseases 0.000 description 5
• 230000009897 systematic effect Effects 0.000 description 5
• YHGNXQAFNHCBTK-OWOJBTEDSA-N trans-3-hexenedioic acid Chemical compound OC(=O)C\C=C\CC(O)=O YHGNXQAFNHCBTK-OWOJBTEDSA-N 0.000 description 5
• IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 5
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
• 206010006100 Bradykinesia Diseases 0.000 description 4
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 4
• 206010061818 Disease progression Diseases 0.000 description 4
• 208000006083 Hypokinesia Diseases 0.000 description 4
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 238000000692 Student's t-test Methods 0.000 description 4
• 206010047571 Visual impairment Diseases 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 230000002929 anti-fatigue Effects 0.000 description 4
• 125000004429 atom Chemical group 0.000 description 4
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
• 244000309464 bull Species 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 230000008602 contraction Effects 0.000 description 4
• 238000011461 current therapy Methods 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 230000005750 disease progression Effects 0.000 description 4
• 210000003238 esophagus Anatomy 0.000 description 4
• 125000004494 ethyl ester group Chemical group 0.000 description 4
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 4
• 150000002430 hydrocarbons Chemical class 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 206010027175 memory impairment Diseases 0.000 description 4
• 125000002757 morpholinyl group Chemical group 0.000 description 4
• 239000001301 oxygen Substances 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 230000009023 proprioceptive sensation Effects 0.000 description 4
• 230000000306 recurrent effect Effects 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 230000001052 transient effect Effects 0.000 description 4
• 208000029257 vision disease Diseases 0.000 description 4
• 230000004393 visual impairment Effects 0.000 description 4
• 239000002023 wood Substances 0.000 description 4
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 3
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
• XLYMOEINVGRTEX-ONEGZZNKSA-N (e)-4-ethoxy-4-oxobut-2-enoic acid Chemical compound CCOC(=O)\C=C\C(O)=O XLYMOEINVGRTEX-ONEGZZNKSA-N 0.000 description 3
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
• 208000000187 Abnormal Reflex Diseases 0.000 description 3
• 208000025978 Athletic injury Diseases 0.000 description 3
• 208000006373 Bell palsy Diseases 0.000 description 3
• 229910052684 Cerium Inorganic materials 0.000 description 3
• 208000032382 Ischaemic stroke Diseases 0.000 description 3
• 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical group CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
• 206010036790 Productive cough Diseases 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 125000001931 aliphatic group Chemical group 0.000 description 3
• 229910052782 aluminium Inorganic materials 0.000 description 3
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 210000003050 axon Anatomy 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 230000017531 blood circulation Effects 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 3
• 230000019771 cognition Effects 0.000 description 3
• 230000003930 cognitive ability Effects 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000003412 degenerative effect Effects 0.000 description 3
• 150000001975 deuterium Chemical group 0.000 description 3
• 229960003638 dopamine Drugs 0.000 description 3
• 210000003743 erythrocyte Anatomy 0.000 description 3
• 210000002683 foot Anatomy 0.000 description 3
• 235000019253 formic acid Nutrition 0.000 description 3
• XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 125000004464 hydroxyphenyl group Chemical group 0.000 description 3
• 230000035859 hyperreflexia Effects 0.000 description 3
• 206010020745 hyperreflexia Diseases 0.000 description 3
• 238000001802 infusion Methods 0.000 description 3
• 210000002414 leg Anatomy 0.000 description 3
• OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 235000019645 odor Nutrition 0.000 description 3
• 238000003305 oral gavage Methods 0.000 description 3
• 230000008520 organization Effects 0.000 description 3
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
• 230000003285 pharmacodynamic effect Effects 0.000 description 3
• 125000004193 piperazinyl group Chemical group 0.000 description 3
• 238000013439 planning Methods 0.000 description 3
• 238000002600 positron emission tomography Methods 0.000 description 3
• 208000037821 progressive disease Diseases 0.000 description 3
• 235000019260 propionic acid Nutrition 0.000 description 3
• 210000004129 prosencephalon Anatomy 0.000 description 3
• 235000018102 proteins Nutrition 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• 125000003226 pyrazolyl group Chemical group 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 230000011514 reflex Effects 0.000 description 3
• 230000000241 respiratory effect Effects 0.000 description 3
• 230000009528 severe injury Effects 0.000 description 3
• 210000000278 spinal cord Anatomy 0.000 description 3
• 210000003802 sputum Anatomy 0.000 description 3
• 208000024794 sputum Diseases 0.000 description 3
• 125000000547 substituted alkyl group Chemical group 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• 230000000007 visual effect Effects 0.000 description 3
• 210000004885 white matter Anatomy 0.000 description 3
• MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 2
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 2
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
• 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 2
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
• 206010001497 Agitation Diseases 0.000 description 2
• 208000000044 Amnesia Diseases 0.000 description 2
• 206010002942 Apathy Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• QJFGYIAJSVAWAO-AATRIKPKSA-N COC(=O)C/C=C/CC(=O)OCCCCOC(=O)C1CCCCC1 Chemical compound COC(=O)C/C=C/CC(=O)OCCCCOC(=O)C1CCCCC1 QJFGYIAJSVAWAO-AATRIKPKSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000282461 Canis lupus Species 0.000 description 2
• 239000004215 Carbon black (E152) Substances 0.000 description 2
• 101150065749 Churc1 gene Proteins 0.000 description 2
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
• 208000016192 Demyelinating disease Diseases 0.000 description 2
• 206010012305 Demyelination Diseases 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 208000014094 Dystonic disease Diseases 0.000 description 2
• 208000004929 Facial Paralysis Diseases 0.000 description 2
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
• 241000167880 Hirundinidae Species 0.000 description 2
• 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 206010021639 Incontinence Diseases 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 108090000467 Interferon-beta Proteins 0.000 description 2
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
• 206010026749 Mania Diseases 0.000 description 2
• 208000026139 Memory disease Diseases 0.000 description 2
• 206010049565 Muscle fatigue Diseases 0.000 description 2
• 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 2
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 102100038239 Protein Churchill Human genes 0.000 description 2
• 206010037714 Quadriplegia Diseases 0.000 description 2
• 238000011831 SOD1-G93A transgenic mouse Methods 0.000 description 2
• 206010041738 Sports injury Diseases 0.000 description 2
• 206010065954 Stubbornness Diseases 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 2
• 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 2
• 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 2
• 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 230000001668 ameliorated effect Effects 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
• 239000000164 antipsychotic agent Substances 0.000 description 2
• 229940005529 antipsychotics Drugs 0.000 description 2
• 210000000617 arm Anatomy 0.000 description 2
• 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
• 208000013404 behavioral symptom Diseases 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 210000000133 brain stem Anatomy 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 230000007850 degeneration Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000000779 depleting effect Effects 0.000 description 2
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• 208000010118 dystonia Diseases 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 230000008921 facial expression Effects 0.000 description 2
• 238000009661 fatigue test Methods 0.000 description 2
• 230000005057 finger movement Effects 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 230000004927 fusion Effects 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 210000004247 hand Anatomy 0.000 description 2
• 125000004404 heteroalkyl group Chemical group 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 229930195733 hydrocarbon Natural products 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 230000001965 increasing effect Effects 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 229960001388 interferon-beta Drugs 0.000 description 2
• 230000035987 intoxication Effects 0.000 description 2
• 231100000566 intoxication Toxicity 0.000 description 2
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 210000003127 knee Anatomy 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 229960004502 levodopa Drugs 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 230000007787 long-term memory Effects 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000011976 maleic acid Substances 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 208000023060 memory loss Diseases 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000004118 muscle contraction Effects 0.000 description 2
• 210000003007 myelin sheath Anatomy 0.000 description 2
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 230000007971 neurological deficit Effects 0.000 description 2
• 230000002232 neuromuscular Effects 0.000 description 2
• 150000002825 nitriles Chemical class 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 239000011713 pantothenic acid Substances 0.000 description 2
• 235000019161 pantothenic acid Nutrition 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 230000008447 perception Effects 0.000 description 2
• 238000011056 performance test Methods 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 238000000554 physical therapy Methods 0.000 description 2
• 150000004885 piperazines Chemical class 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 235000021251 pulses Nutrition 0.000 description 2
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
• 125000005493 quinolyl group Chemical group 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000010079 rubber tapping Methods 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000037152 sensory function Effects 0.000 description 2
• 230000006403 short-term memory Effects 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 238000013112 stability test Methods 0.000 description 2
• 125000003107 substituted aryl group Chemical group 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 239000011593 sulfur Chemical group 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 229940121136 tecfidera Drugs 0.000 description 2
• 230000002123 temporal effect Effects 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• 230000004382 visual function Effects 0.000 description 2
• 230000001755 vocal effect Effects 0.000 description 2
• 230000003313 weakening effect Effects 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• NDQQRRVKUBPTHQ-QBIQUQHTSA-N (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO NDQQRRVKUBPTHQ-QBIQUQHTSA-N 0.000 description 1
• DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
• 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
• 125000006647 (C3-C15) cycloalkyl group Chemical group 0.000 description 1
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• INCZZGBUDPSWRN-MDZDMXLPSA-N (e)-2-(4-morpholin-4-ylbutyl)but-2-enedioic acid Chemical compound OC(=O)\C=C(C(O)=O)/CCCCN1CCOCC1 INCZZGBUDPSWRN-MDZDMXLPSA-N 0.000 description 1
• XGCKGSYWJABUGN-NSCUHMNNSA-N (e)-6-methoxy-6-oxohex-3-enoic acid Chemical compound COC(=O)C\C=C\CC(O)=O XGCKGSYWJABUGN-NSCUHMNNSA-N 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 1
• OLSWMZAVJQIFBT-AATRIKPKSA-N 1-o-methyl 4-o-(5-morpholin-4-ylpentyl) (e)-but-2-enedioate Chemical compound COC(=O)\C=C\C(=O)OCCCCCN1CCOCC1 OLSWMZAVJQIFBT-AATRIKPKSA-N 0.000 description 1
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
• 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 description 1
• SGBICHSMBOYOFD-UHFFFAOYSA-N 2,3-dibromo-7-iododibenzo-p-dioxin Chemical compound O1C2=CC=C(I)C=C2OC2=C1C=C(Br)C(Br)=C2 SGBICHSMBOYOFD-UHFFFAOYSA-N 0.000 description 1
• 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• CGMMPMYKMDITEA-UHFFFAOYSA-N 2-ethylbenzoic acid Chemical compound CCC1=CC=CC=C1C(O)=O CGMMPMYKMDITEA-UHFFFAOYSA-N 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• YQDGQEKUTLYWJU-UHFFFAOYSA-N 5,6,7,8-tetrahydroquinoline Chemical compound C1=CC=C2CCCCC2=N1 YQDGQEKUTLYWJU-UHFFFAOYSA-N 0.000 description 1
• LMAYDNVIKBCSLP-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NCCC2=N1 LMAYDNVIKBCSLP-UHFFFAOYSA-N 0.000 description 1
• XGCKGSYWJABUGN-UHFFFAOYSA-N 6-methoxy-6-oxohex-3-enoic acid Chemical compound COC(=O)CC=CCC(O)=O XGCKGSYWJABUGN-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 208000035657 Abasia Diseases 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• IKZCZWRSOHRMEH-AATRIKPKSA-N C1(=CC=CC=C1)C(=O)OCCOC(=O)C/C=C/CC(=O)OC Chemical compound C1(=CC=CC=C1)C(=O)OCCOC(=O)C/C=C/CC(=O)OC IKZCZWRSOHRMEH-AATRIKPKSA-N 0.000 description 1
• TZVUHKCSQZSNOS-BQYQJAHWSA-N CC(C(OC(=O)C1=CC=CC=C1)OC(=O)C/C=C/CC(=O)OC)C Chemical compound CC(C(OC(=O)C1=CC=CC=C1)OC(=O)C/C=C/CC(=O)OC)C TZVUHKCSQZSNOS-BQYQJAHWSA-N 0.000 description 1
• RLHSZIVNNPZRQM-ONEGZZNKSA-N CC(C)COCCOC(C/C=C/CC(O)=O)=O Chemical compound CC(C)COCCOC(C/C=C/CC(O)=O)=O RLHSZIVNNPZRQM-ONEGZZNKSA-N 0.000 description 1
• SCWMGLIGTUUXDH-ONEGZZNKSA-N COC(=O)/C=C/COCC(=O)N(C)CC(=O)O Chemical compound COC(=O)/C=C/COCC(=O)N(C)CC(=O)O SCWMGLIGTUUXDH-ONEGZZNKSA-N 0.000 description 1
• WVZBAJKSQMHJNW-UFFNRZRYSA-N COC(=O)C/C=C/CC(=O)O[C@H](C(=O)N1CCOCC1)C Chemical compound COC(=O)C/C=C/CC(=O)O[C@H](C(=O)N1CCOCC1)C WVZBAJKSQMHJNW-UFFNRZRYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 235000008474 Cardamine pratensis Nutrition 0.000 description 1
• 240000000606 Cardamine pratensis Species 0.000 description 1
• GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
• 206010008531 Chills Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000032862 Clinical Deterioration Diseases 0.000 description 1
• 206010010219 Compulsions Diseases 0.000 description 1
• 206010010305 Confusional state Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 206010010947 Coordination abnormal Diseases 0.000 description 1
• 241001573881 Corolla Species 0.000 description 1
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
• PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
• 201000010374 Down Syndrome Diseases 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 108010072051 Glatiramer Acetate Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 208000011092 Hand injury Diseases 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
• 101000844686 Homo sapiens Thioredoxin reductase 1, cytoplasmic Proteins 0.000 description 1
• 101150043003 Htt gene Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• 206010020852 Hypertonia Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
• 206010021703 Indifference Diseases 0.000 description 1
• 208000025069 Juvenile Huntington disease Diseases 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical class OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 108091077621 MAPRE family Proteins 0.000 description 1
• PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
• 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
• 208000034819 Mobility Limitation Diseases 0.000 description 1
• 206010027940 Mood altered Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 208000029549 Muscle injury Diseases 0.000 description 1
• 206010028347 Muscle twitching Diseases 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010056677 Nerve degeneration Diseases 0.000 description 1
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
• 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
• 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
• 206010033864 Paranoia Diseases 0.000 description 1
• 208000027099 Paranoid disease Diseases 0.000 description 1
• 206010034719 Personality change Diseases 0.000 description 1
• 206010034720 Personality change due to a general medical condition Diseases 0.000 description 1
• 244000046052 Phaseolus vulgaris Species 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
• QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 206010039740 Screaming Diseases 0.000 description 1
• 206010039966 Senile dementia Diseases 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 102100031208 Thioredoxin reductase 1, cytoplasmic Human genes 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 206010044688 Trisomy 21 Diseases 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 210000003423 ankle Anatomy 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 229940005524 anti-dementia drug Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 229960004046 apomorphine Drugs 0.000 description 1
• VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 150000001541 aziridines Chemical class 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 210000000746 body region Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 229960002802 bromocriptine Drugs 0.000 description 1
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229960004205 carbidopa Drugs 0.000 description 1
• TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
• 150000001722 carbon compounds Chemical class 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 150000003857 carboxamides Chemical class 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 229940121657 clinical drug Drugs 0.000 description 1
• DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
• 229960003120 clonazepam Drugs 0.000 description 1
• 230000006998 cognitive state Effects 0.000 description 1
• 230000036992 cognitive tasks Effects 0.000 description 1
• 210000001520 comb Anatomy 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000010411 cooking Methods 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
• 150000005690 diesters Chemical class 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• WVZVZUBVJBYPTK-UHFFFAOYSA-N dispiro[2.2.46.23]dodecane Chemical compound C1CC11CCC2(CCCC2)CC1 WVZVZUBVJBYPTK-UHFFFAOYSA-N 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 230000000632 dystonic effect Effects 0.000 description 1
• 230000008451 emotion Effects 0.000 description 1
• 230000008909 emotion recognition Effects 0.000 description 1
• 230000006397 emotional response Effects 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 150000002118 epoxides Chemical class 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
• QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 229960000556 fingolimod Drugs 0.000 description 1
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 210000001652 frontal lobe Anatomy 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229940114119 gentisate Drugs 0.000 description 1
• 229960003776 glatiramer acetate Drugs 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229940097042 glucuronate Drugs 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 235000003969 glutathione Nutrition 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 239000001307 helium Substances 0.000 description 1
• 229910052734 helium Inorganic materials 0.000 description 1
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 208000030309 inherited neurodegenerative disease Diseases 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 230000003933 intellectual function Effects 0.000 description 1
• 210000000876 intercostal muscle Anatomy 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 229940045996 isethionic acid Drugs 0.000 description 1
• TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 210000001847 jaw Anatomy 0.000 description 1
• 230000009916 joint effect Effects 0.000 description 1
• 235000021332 kidney beans Nutrition 0.000 description 1
• 208000028756 lack of coordination Diseases 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 210000004717 laryngeal muscle Anatomy 0.000 description 1
• 230000013016 learning Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
• 208000027061 mild cognitive impairment Diseases 0.000 description 1
• 230000009525 mild injury Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 230000009526 moderate injury Effects 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 230000007510 mood change Effects 0.000 description 1
• 230000037023 motor activity Effects 0.000 description 1
• 210000000337 motor cortex Anatomy 0.000 description 1
• 230000004220 muscle function Effects 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000001577 neostriatum Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 239000002664 nootropic agent Substances 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 230000010355 oscillation Effects 0.000 description 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 238000010422 painting Methods 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 229940055726 pantothenic acid Drugs 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 229960004838 phosphoric acid Drugs 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 150000004032 porphyrins Chemical class 0.000 description 1
• 229960003089 pramipexole Drugs 0.000 description 1
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000012913 prioritisation Methods 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 229940095574 propionic acid Drugs 0.000 description 1
• 230000000272 proprioceptive effect Effects 0.000 description 1
• 125000006308 propyl amino group Chemical group 0.000 description 1
• 230000004800 psychological effect Effects 0.000 description 1
• 210000002763 pyramidal cell Anatomy 0.000 description 1
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
• 229960003147 reserpine Drugs 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000001020 rhythmical effect Effects 0.000 description 1
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
• 229960001879 ropinirole Drugs 0.000 description 1
• MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
• 230000004434 saccadic eye movement Effects 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 235000019615 sensations Nutrition 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000036362 sensorimotor function Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 208000037974 severe injury Diseases 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 229910052710 silicon Inorganic materials 0.000 description 1
• 230000005808 skin problem Effects 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• IWDANOJGJIFBEL-UHFFFAOYSA-N spiro[3.4]octane Chemical compound C1CCC21CCCC2 IWDANOJGJIFBEL-UHFFFAOYSA-N 0.000 description 1
• CTDQAGUNKPRERK-UHFFFAOYSA-N spirodecane Chemical compound C1CCCC21CCCCC2 CTDQAGUNKPRERK-UHFFFAOYSA-N 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 229960004274 stearic acid Drugs 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000012030 stroop test Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 230000000153 supplemental effect Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000007470 synaptic degeneration Effects 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• KKEYFWRCBNTPAC-UHFFFAOYSA-L terephthalate(2-) Chemical compound [O-]C(=O)C1=CC=C(C([O-])=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-L 0.000 description 1
• 229960000331 teriflunomide Drugs 0.000 description 1
• UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
• 229960005333 tetrabenazine Drugs 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 150000003585 thioureas Chemical class 0.000 description 1
• 210000003813 thumb Anatomy 0.000 description 1
• 239000003204 tranquilizing agent Substances 0.000 description 1
• 230000002936 tranquilizing effect Effects 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
• 229960000604 valproic acid Drugs 0.000 description 1
• NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 229940025158 xenazine Drugs 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1